Search > Myelofibrosis
My employer runs this trial

Luspatercept + Pacritinib for Myelofibrosis

AJ
Overseen ByAkriti Jain, MD, FACP
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Case Comprehensive Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.

Who Is on the Research Team?

AJ

Akriti Jain, MD, FACP

Principal Investigator

The Cleveland Clinic

Are You a Good Fit for This Trial?

This trial is for people with myelofibrosis who also have low blood counts, including anemia (low red cells) and thrombocytopenia (low platelets). Participants should not have other serious health issues that would prevent them from joining.

Inclusion Criteria

I have myelofibrosis with anemia or low platelets.
I am able to care for myself and do light activities.
Ability and willingness to sign informed consent
See 5 more

Exclusion Criteria

I have not used Luspatercept, Sotatercept, Elritercept, activin ligand traps, pacritinib, or Momelotinib. I may have used Ruxolitinib or Fedratinib if I stopped at least 2 weeks ago.
Participation in other clinical trials with experimental therapy or devices within 30 days or five half-lives of investigational agents before screening
I have had allergic reactions to drugs like luspatercept or pacritinib.
See 14 more

What Are the Treatments Tested in This Trial?

Interventions

  • Luspatercept
  • Pacritinib

Trial Overview

The study tests a combination of two experimental drugs, Luspatercept and Pacritinib, to see if they can improve hemoglobin levels or reduce the need for blood transfusions in people with myelofibrosis and low blood counts.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: LusPACercept combinationExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials
472
Recruited
33,400+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.